Key Points
- STERIS CEO Daniel Carestio sold 3,054 shares on June 4 at an average price of $214.64, totaling about $655,511. The sale was made under a pre-arranged Rule 10b5-1 plan, and he still directly owns 65,021 shares.
- The stock was down about 1% in Tuesday trading, opening at $210.19. STERIS currently has a market cap of $20.52 billion and trades below both its 50-day and 200-day moving averages.
- STERIS recently posted mixed quarterly results and paid a dividend, reporting EPS of $2.83 versus an expected $2.86 while revenue rose 6.7% year over year to $1.59 billion. The company also declared a quarterly dividend of $0.63 per share, payable June 26.
STERIS plc (NYSE:STE - Get Free Report) CEO Daniel Carestio sold 1,374 shares of the firm's stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $212.00, for a total transaction of $291,288.00. Following the completion of the transaction, the chief executive officer directly owned 63,647 shares in the company, valued at approximately $13,493,164. This represents a 2.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
STERIS Stock Performance
NYSE:STE opened at $210.19 on Tuesday. The company's 50-day moving average price is $216.98 and its 200-day moving average price is $238.63. The company has a current ratio of 2.09, a quick ratio of 1.54 and a debt-to-equity ratio of 0.25. The company has a market cap of $20.52 billion, a P/E ratio of 26.51 and a beta of 0.93. STERIS plc has a twelve month low of $195.14 and a twelve month high of $269.44.
STERIS (NYSE:STE - Get Free Report) last posted its quarterly earnings results on Monday, May 11th. The medical equipment provider reported $2.83 earnings per share for the quarter, missing the consensus estimate of $2.86 by ($0.03). The business had revenue of $1.59 billion during the quarter, compared to analysts' expectations of $1.59 billion. STERIS had a return on equity of 14.15% and a net margin of 13.18%.The business's quarterly revenue was up 6.7% on a year-over-year basis. During the same period in the prior year, the business posted $2.74 earnings per share. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. On average, sell-side analysts forecast that STERIS plc will post 11.18 earnings per share for the current fiscal year.
STERIS Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, June 26th. Shareholders of record on Monday, June 8th will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Monday, June 8th. This represents a $2.52 dividend on an annualized basis and a yield of 1.2%. STERIS's payout ratio is 31.78%.
Analysts Set New Price Targets
A number of equities analysts have commented on the stock. Wall Street Zen downgraded shares of STERIS from a "strong-buy" rating to a "buy" rating in a research note on Saturday. Piper Sandler reaffirmed an "overweight" rating and set a $270.00 target price on shares of STERIS in a research note on Thursday, May 21st. KeyCorp reduced their target price on shares of STERIS from $291.00 to $269.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 13th. Finally, Weiss Ratings downgraded shares of STERIS from a "hold (c+)" rating to a "hold (c)" rating in a research note on Wednesday, May 27th. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $278.00.
Check Out Our Latest Stock Report on STERIS
Institutional Investors Weigh In On STERIS
A number of institutional investors and hedge funds have recently made changes to their positions in STE. Jones Financial Companies Lllp raised its stake in shares of STERIS by 46.1% in the 1st quarter. Jones Financial Companies Lllp now owns 1,106 shares of the medical equipment provider's stock valued at $251,000 after acquiring an additional 349 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of STERIS by 32.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 242,732 shares of the medical equipment provider's stock valued at $55,015,000 after acquiring an additional 59,264 shares during the period. Empowered Funds LLC raised its stake in shares of STERIS by 16.1% in the 1st quarter. Empowered Funds LLC now owns 2,303 shares of the medical equipment provider's stock valued at $522,000 after acquiring an additional 319 shares during the period. Woodline Partners LP raised its stake in shares of STERIS by 40.0% in the 1st quarter. Woodline Partners LP now owns 8,300 shares of the medical equipment provider's stock valued at $1,881,000 after acquiring an additional 2,372 shares during the period. Finally, Jane Street Group LLC raised its stake in shares of STERIS by 38.9% in the 1st quarter. Jane Street Group LLC now owns 20,716 shares of the medical equipment provider's stock valued at $4,695,000 after acquiring an additional 5,803 shares during the period. 94.69% of the stock is owned by hedge funds and other institutional investors.
STERIS Company Profile
(
Get Free Report)
STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.
Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
